Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT C
Section 16. Form 4 or Form 5	
obligations may continue. See	

OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Singh Shawn					2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VSTA]										eck all ap		orting Pe	rson(s) to Iss 10% Ov			
	(F TAGEN T LERTON A		3. Date of Earliest Transaction (Month/Day/Year) 10/15/2013										^ belo	w) (specify ER				
(Street) SOUTH SAN FRANCISCO CA 94080					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																		
		Tak	le I - Nor	n-Deriv	/ativ	e Se	curit	ies Ac	qu	ired, D	isp	osed o	f, or	Bene	eficial	y Own	ed				
Date				te onth/Day/Year)			eemed ition Date h/Day/Yea	·,	3. Transaction Dispose Code (Instr. 8)								For (D)	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	,	Amount		(A) or (D)	Price	Trans	action(s) . 3 and 4)			(113111 4)	
Common	Stock			10/15	5/201	13				М		10,00	0	A	\$0.64	4 3	312,174		I By Trust ⁽¹⁾		
			Table II -									sed of, onvertil				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, 1	l. Fransaction Code (Instr. B)				Ex	Date Exer piration E onth/Day/	ate		of Se Unde Deriv	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5)	deriva Secur Benef Owne Follow Repor	rities ficially d wing rted action(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				ı	Code	v	(A)	(D)	Da Ex	te ercisable		xpiration ate	Title	1	Amount or Number of Shares						
Warrant	\$0.64	10/15/2013			M			10,000		(2)	03	3/03/2023	Com	mon ck	10,000	\$0	1,4	40,000	D		

Explanation of Responses:

1. Held by The 1997 Singh Family Trust U/R/D 5/29/97

/s/ Jerrold D. Dotson, Attorney-10/15/2013 in-Fact, Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Subject to the Reporting Person's continuous service, and as incentive to continue employment and build shareholder value, the Warrant will vest according to the following schedule: 50% of the total number of shares on April 1, 2013 (the "Vesting Start Date"); 25% of the total number of shares on the one year anniversary of the Vesting Start Date; provided, however, that the Warrant shall vest in full upon a change in control of the Company, or upon the consummation by the Company and a third-party of a license or sale transaction involving at least one (1) new drug rescue variant developed by the Company.